Chris Lau

Chris Lau

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Microsoft Stock Is Still Compelling After Recent Rally

MSFT stock is being boosted by the growth of Office 365 and Azure. Yet the digital transformation is a big contributor to MSFT's growth, too.

Acquisition Improves the Outlook of Pfizer Stock

Array's cancer drug pipeline, which has many advanced, high-potential treatments, can boost Pfizer stock price over the long-term.

Why Aurora Cannabis Stock Might Fall to $6 Per Share Soon

ACB stock has negative read throughs from Canaopy Growth's results. however, Aurora stock has a number of other positive catalysts.

The Uptrend in Intel Stock Is Likely to Stall Before Too Long

AMD is getting all the glory while Intel is in the dog house. The 10nm delay and a cautious outlook is hurting Intel stock. What's next?

Will Disney Stock Dip as Shares Touch 52-Week Highs?

Disney Stock gained billions in market cap since announcing Disney+ in April. It could be time for a healthy pullback in DIS.

Tesla’s Results to Be Pivotal for TSLA Stock

Markets have high expectations for TSLA. It might exceed them in the quarter, boosting Tesla stock towards analysts' average price target..

Why Advanced Micro Devices Stock Pulled Back From $34 In The Past Week

Though Advanced Micro Devices stock fell from 52-week highs, AMD stock is still in an uptrend. What will keep the shares moving up?

Nio Stock Increasingly Looks Like It’s Worth Revisiting

Nio reported unit sales of ES8 exceeding its own estimates. This may be the beginning of Nio stock resurgence.

The Short-Term Earnings Numbers for CGC Stock Aren’t Most Important

Shares of CGC stock will move after its earnings report, but what really matters is the long-term growth narrative for Canopy.

CVS Stock Has More Going for It Than Just a 3.69% Dividend Yield

A judge is challenging the CVS Health-Aetna deal and the drug store sector is out of favor. So when will the discount on CVS stock end?